Literature DB >> 21364029

Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.

Amanda I Phipps1, Rowan T Chlebowski, Ross Prentice, Anne McTiernan, Marcia L Stefanick, Jean Wactawski-Wende, Lewis H Kuller, Lucile L Adams-Campbell, Dorothy Lane, Mara Vitolins, Geoffrey C Kabat, Thomas E Rohan, Christopher I Li.   

Abstract

BACKGROUND: Triple-negative breast cancer, characterized by a lack of hormone receptor and HER2 expression, is associated with a particularly poor prognosis. Focusing on potentially modifiable breast cancer risk factors, we examined the relationship between body size, physical activity, and triple-negative disease risk.
METHODS: Using data from 155,723 women enrolled in the Women's Health Initiative (median follow-up, 7.9 years), we assessed associations between baseline body mass index (BMI), BMI in earlier adulthood, waist and hip circumference, waist-hip ratio, recreational physical activity, and risk of triple-negative (n=307) and estrogen receptor-positive (ER+, n=2,610) breast cancers.
RESULTS: Women in the highest versus lowest BMI quartile had 1.35-fold (95% CI, 0.92-1.99) and 1.39-fold (95% CI, 1.22-1.58) increased risks of triple-negative and ER+ breast cancers, respectively. Waist and hip circumferences were positively associated with risk of ER+ breast cancer (Ptrend=0.01 for both measures) but were not associated with triple-negative breast cancer. Compared with women who reported no recreational physical activity, women in the highest activity tertile had similarly lower risks of triple-negative and ER+ breast cancers (HR=0.77; 95% CI, 0.51-1.13; and HR=0.85; 95% CI, 0.74-0.98, respectively).
CONCLUSIONS: Despite biological and clinical differences, triple-negative and ER+ breast cancers are similarly associated with BMI and recreational physical activity in postmenopausal women. The biological mechanisms underlying these similarities are uncertain and these modest associations require further investigation. IMPACT: If confirmed, these results suggest potential ways postmenopausal women might modify their risk of both ER+ and triple-negative breast cancers. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21364029      PMCID: PMC3064558          DOI: 10.1158/1055-9965.EPI-10-0974

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  The Women's Health Initiative recruitment methods and results.

Authors:  Jennifer Hays; Julie R Hunt; F Allan Hubbell; Garnet L Anderson; Marian Limacher; Catherine Allen; Jacques E Rossouw
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

Review 2.  Upper abdominal obesity, insulin resistance and breast cancer risk.

Authors:  B A Stoll
Journal:  Int J Obes Relat Metab Disord       Date:  2002-06

3.  Compendium of physical activities: classification of energy costs of human physical activities.

Authors:  B E Ainsworth; W L Haskell; A S Leon; D R Jacobs; H J Montoye; J F Sallis; R S Paffenbarger
Journal:  Med Sci Sports Exerc       Date:  1993-01       Impact factor: 5.411

4.  Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.

Authors:  S M Enger; R K Ross; A Paganini-Hill; C L Carpenter; L Bernstein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-07       Impact factor: 4.254

5.  Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.

Authors:  P A Kern; S Ranganathan; C Li; L Wood; G Ranganathan
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-05       Impact factor: 4.310

6.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Authors:  William D Foulkes; Ingunn M Stefansson; Pierre O Chappuis; Louis R Bégin; John R Goffin; Nora Wong; Michel Trudel; Lars A Akslen
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

7.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

8.  Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study.

Authors:  Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

9.  Risk factors for breast cancer according to estrogen and progesterone receptor status.

Authors:  Graham A Colditz; Bernard A Rosner; Wendy Y Chen; Michelle D Holmes; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2004-02-04       Impact factor: 13.506

10.  Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.

Authors:  T J Key; P N Appleby; G K Reeves; A Roddam; J F Dorgan; C Longcope; F Z Stanczyk; H E Stephenson; R T Falk; R Miller; A Schatzkin; D S Allen; I S Fentiman; T J Key; D Y Wang; M Dowsett; H V Thomas; S E Hankinson; P Toniolo; A Akhmedkhanov; K Koenig; R E Shore; A Zeleniuch-Jacquotte; F Berrino; P Muti; A Micheli; V Krogh; S Sieri; V Pala; E Venturelli; G Secreto; E Barrett-Connor; G A Laughlin; M Kabuto; S Akiba; R G Stevens; K Neriishi; C E Land; J A Cauley; L H Kuller; S R Cummings; K J Helzlsouer; A J Alberg; T L Bush; G W Comstock; G B Gordon; S R Miller; C Longcope
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

View more
  77 in total

Review 1.  Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Authors:  Mark F Munsell; Brian L Sprague; Donald A Berry; Gary Chisholm; Amy Trentham-Dietz
Journal:  Epidemiol Rev       Date:  2014       Impact factor: 6.222

2.  Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.

Authors:  Katie M O'Brien; Stephen R Cole; Lawrence S Engel; Jeannette T Bensen; Charles Poole; Amy H Herring; Robert C Millikan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-31       Impact factor: 4.254

3.  Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?

Authors:  Debarshi Jana; Diptendra Kumar Sarkar; Suvro Ganguly; Abhirup Banerjee; Asim Kumar Manna; Syamsundar Mandal
Journal:  Indian J Surg Oncol       Date:  2014-04-06

4.  Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer.

Authors:  Vanessa B Sheppard; Luciane R Cavalli; Chiranjeev Dash; Yasmine M Kanaan; Asma A Dilawari; Sara Horton; Kepher H Makambi
Journal:  Clin Breast Cancer       Date:  2017-01-06       Impact factor: 3.225

5.  Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.

Authors:  Carol Sweeney; Philip S Bernard; Rachel E Factor; Marilyn L Kwan; Laurel A Habel; Charles P Quesenberry; Kaylynn Shakespear; Erin K Weltzien; Inge J Stijleman; Carole A Davis; Mark T W Ebbert; Adrienne Castillo; Lawrence H Kushi; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

6.  Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Authors:  Christopher I Li; Justin E Mirus; Yuzheng Zhang; Arturo B Ramirez; Jon J Ladd; Ross L Prentice; Martin W McIntosh; Samir M Hanash; Paul D Lampe
Journal:  Breast Cancer Res Treat       Date:  2012-08-19       Impact factor: 4.872

7.  Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.

Authors:  Nicholas K Howland; Teryn D Driver; Michael P Sedrak; Xianfeng Wen; Wenli Dong; Sandra Hatch; Mahmoud A Eltorky; Celia Chao
Journal:  J Surg Res       Date:  2013-07-11       Impact factor: 2.192

8.  Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.

Authors:  Jennifer A Crozier; Alvaro Moreno-Aspitia; Karla V Ballman; Amylou C Dueck; Barbara A Pockaj; Edith A Perez
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

9.  Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.

Authors:  Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

10.  Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.

Authors:  Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.